Loading stock data…
MDCX
$0.29+0.00 (+0.96%)
Market ClosedLast close May 1
Medicus Pharma Ltd., a biotech/life sciences company, focuses on developing clinical development programs of therapeutic assets in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Medicus Pharma Ltd. in the Healthcare sector is trading at $0.29. The stock is currently near its 52-week low of $0.27, remaining 82.9% below its 200-day moving average. Technical signals show oversold RSI of 25 and bullish MACD crossover, explaining why MDCX maintains its current current market pressure. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Oversold momentum (RSI 25) — potential for technical mean-reversion
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$0.29
Potential Upside
5%
Whystock Fair Value$0.30
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Medicus Pharma Ltd., a biotech/life sciences company, focuses on developing clinical development programs of therapeutic assets in the United States. It is developing SKNJCT-003, which is in Phase 2 study for the treatment of basal cell carcinoma of ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$13.34M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
-0.04
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
52467.97%
Volume
Today's trading volume
1.09M
Recent News
Medicus Pharma lobbies Congress on SkinJect regulatory pathway for rare Gorlin syndrome
Medicus Pharma (NASDAQ:MDCX) said on Monday its chief executive and senior leadership team met with US lawmakers on Capitol Hill to seek support for regulatory and policy measures aimed at advancing its SkinJect therapy for patients with Gorlin syndrome, a rare inherited condition linked to...
Medicus Pharma advances Skinject in rare disease – ICYMI
Medicus Pharma (NASDAQ:MDCX) earlier this week outlined progress in advancing its Skinject program, highlighting a newly submitted orphan drug designation application with the US Food and Drug Administration targeting Gorlin syndrome, a rare genetic condition with no approved treatments. In...
Medicus Pharma files Orphan Drug application for SkinJect in rare skin Cancer indication
Medicus Pharma CEO Dr Raza Bokhari joined Steve Darling from Proactive to announce that the company has submitted an Orphan Drug Designation application to the U.S. Food and Drug Administration for SkinJect® as a treatment for basal cell carcinoma in patients with Gorlin Syndrome. Bokhari explained that the submission represents a strategic expansion of the SkinJect program into a high unmet-need orphan indication, where current treatment options are limited and often require repeated surgical procedures that can lead to cumulative morbidity and disfigurement. Gorlin Syndrome, also known as nevoid basal cell carcinoma syndrome, is a rare inherited disorder typically caused by mutations in the PTCH1 gene. This leads to dysregulation of the Hedgehog signaling pathway and the development of multiple, recurring skin cancers. Patients may develop dozens to more than 1,000 basal cell carcinomas over their lifetime, often beginning in childhood, creating a significant physical and psychological burden. Currently, there are no FDA-approved therapies specifically for basal cell carcinoma in patients with Gorlin Syndrome, with treatment largely reliant on surgical excision or Mohs surgery. Medicus believes SkinJect® could address this gap through a localized, repeatable, and non-surgical approach. The therapy is a doxorubicin-based dissolvable microneedle array designed for direct intradermal delivery into basal cell carcinoma lesions, targeting tumors at the site while minimizing systemic exposure. The company sees this program as an opportunity to provide a more patient-friendly treatment option for a population with significant unmet medical need. Medicus also noted it has sufficient financial runway into next year to support continued advancement of its clinical programs and key development milestones. #proactiveinvestors #nasdaq #mdcx #tsxv #mdcx #pharma #SkinJect #OrphanDrug #RareDisease #GorlinSyndrome #BasalCellCarcinoma #SkinCancer #Biotech #DrugDevelopment #FDA #Oncology #MedicalInnovation #Healthcare #Microneedle #PatientCare
Medicus Pharma seeks orphan drug status for SkinJect in rare skin cancer disorder
Medicus Pharma (NASDAQ:MDCX) said on Friday it has submitted an application to the US Food and Drug Administration seeking orphan drug designation for its SkinJect therapy to treat basal cell carcinoma in patients with Gorlin Syndrome, a rare genetic condition marked by recurring skin...
Dow rockets higher as Strait of Hormuz stays open, talks eyed
US benchmark WTI crude fell nearly 11% after Iran’s foreign minister signaled that the Strait of Hormuz would remain open